CAS: 114798-26-4; (1-((2'-(1H-Tetrazol-5-yl)-[1,1'-Biphenyl]-4-yl)Methyl)-2-Butyl-4-Chloro-1H-Imidazol-5-yl)Methanol

该化合物是一种主要用于治疗高血压和保护2型糖尿病患者肾脏的血管活性第二代受体敌体抗体,其特点是能够有选择地阻止血管二型手术,这是一种强大的血管收缩器,从而推动血管血管扩张和减少血压.Losartan的化学配方是C22H23ClN6O,它具有一种带有四联环的双苯结构,有助于其药理特性.Losartan通常进行口服,并表现出相对较长的半衰期,允许每天一次使用.它被吸收在胃肠道中,最高血浆浓度在手术后数小时内发生.该药物主要在肝脏中发生代谢,其活性代谢作用导致其抗体性激素强化效应.常见的副作用可能包括头晕,疲劳和潜在的肾损伤,需要用前肾脏状况对病人进行监测.

结构式图片

欧盟法规

REACH注册ECHA物质C&L通报REACH预注册

上下游产品

CAS号124751-00-4 [2-丁基-4-氯-1-[(2... | CAS号114772-55-3 4'-[(2-丁基-4-氯-5... | CAS号114798-36-6 氯沙坦甲醛 | CAS号124750-99-8 氯沙坦钾 | CAS号133909-99-6 N-Trityl Losart... | CAS号67-56-1 甲醇 | CAS号852357-69-8 (2-butyl-5-chlo... | CAS号18039-42-4 5-苯基四氮唑 | CAS号41882-10-4 N-(4-methoxyben... | CAS号1070175-00-6 3-(methanesulfo... | CAS号2387-23-7 N,N’-二环己基脲 | CAS号1070174-97-8 4-(3-thioxo-3H-... | CAS号124751-00-4 [2-丁基-4-氯-1-[(2... | CAS号138584-34-6 氯沙坦N1-葡萄糖醛酸 | CAS号138584-35-7 氯沙坦N2-葡萄糖醛酸 | CAS号124750-99-8 氯沙坦钾 | CAS号124750-92-1 氯沙坦

合成工艺路线路线简述

    Cozaar置于10体系中,用 水 用作溶剂,化学反应 336.0H,以to Obtain A Concentration Of 2.5 Mg/ml的收率获得洛沙坦
    参考文献:Novel Compositions And Uses Of Anti-Hypertension Agents For Cancer Therapy
    标题:Novel Compositions And Uses Of Anti-Hypertension Agents For Cancer Therapy
    摘要:本发明揭示了用于改善治疗(例如癌症治疗)的递送和/或疗效的方法和组合物.在一种实施例中,揭示了通过向受试者施用降压药物(作为单一药物或与微环境调节剂和/或治疗(例如,治疗剂或治疗疗法,包括免疫疗法(例如,抗体,疫苗,基于细胞的疗法),纳米治疗,放射线治疗,光动力疗法,低分子量化疗药物,分子靶向治疗和/或氧自由基)组合使用)来治疗或预防癌症(例如,实质性肿瘤如纤维化瘤)的方法和组合物.

    海关参考信息

    专利信息


    专利号:US-10889599-B2
    优先权日:2018-02-27
    标 题:1,1-diborylalkyl-1-metal compounds, preparation method thereof, and their applications toward synthesis of 1,1-diboronate ester compounds
    发明人:CHO SEUNG HWAN; LEE YEOSAN
    权利人:POSTECH ACAD IND FOUND
    摘要:The present invention relates to a 1,1-diborylalkyl-1-metal compound including one metal group together with two identical boron groups at the sp3 carbon center, and its use. Specifically, the present invention relates to development of novel organic reactions, synthesis of functional molecules, and synthesis of new drugs by applying the novel 1,1-diboryl-1-metal substituted alkyl compounds to various molecular libraries which could not be synthesized by conventional methodologies.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10973847-B2
    优先权日:2017-06-30
    标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
    发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

    专利号:US-2008214637-A1
    优先权日:2004-11-11
    标题 :Process for the Synthesis of Tetrazoles
    发明人:ANTONCIC LJUBOMIR; LUDESCHER JOHANNES
    权利人:LEK PHARMACEUTICALS
    摘要:A process for the synthesis of tetrazol derivative has been developed which starts from a tetrazole derivative where acidic hydrogen atom has been replaced by a protecting group and the deprotection is performed with a catalytic amount of organic acid and can proceed in an aqueous solvent.

    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-6271375-B1
    优先权日:1997-06-30
    标 题 :Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes
    发明人:VILLA MARCO; ALLEGRINI PIETRO; ARRIGHI KATIUSCIA; PAIOCCHI MAURIZIO
    权利人:ZAMBON SPA
    摘要:A process of direct metalation of phenyltetrazoles useful for preparing compounds of formula (II) intermediates for the synthesis of angiotensin II antagonists is described.
    江西三元药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.sy-pharm.com
    企业联系电话:0796-2620392 2620395👤
    📞江西三元药业有限公司 ⚠️参考联系方式
    联系人:葛先生
    电话:0796-2620392 2620395
    手机:13576851888
    传真:0796-2600130
    邮箱:sales@sy-pharm.com
    通信地址: 江西省新干县大洋洲盐化工业城
    邮编: 331302
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江西省新干县大洋洲盐化工业城
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    扬州施凯化工科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.shsunchem.com
    电话: 86-0514-87851548👤
    📞扬州施凯化工科技有限公司 ⚠️参考联系方式

    销售电话:86-0514-87851548
    邮箱:market@shsunchem.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    台州开创生物医药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.creatingbiopharm.com
    企业联系电话:0576-88827176;18906581668👤
    📞台州开创生物医药有限公司 ⚠️参考联系方式
    联系人:余美平
    电话:0576-88827176;18906581668
    手机:13586099526;18906581668
    传真:0576-88822496
    邮箱:sales@creatingbiopharm.com
    通信地址: 浙江省台州市君悦大厦A幢715
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省台州市君悦大厦A幢715
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    常州市晔泰精细化工研究所
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yetaichem.com
    企业联系电话:0519-83299352👤
    📞常州市晔泰精细化工研究所 ⚠️参考联系方式
    联系人:柳建华;朱立平
    电话:0519-83299352
    手机:013506110093
    传真:0519-83975360
    邮箱:liujh@hi2000.com
    通信地址: 常州市南郊老312国道旁宣塘桥宣盛路9号
    邮编: 213016
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:常州市南郊老312国道旁宣塘桥宣盛路9号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Prasanna N, Subbarao CV, Gutmann JL. The efficacy of pre-operative oral medication of lornoxicam and diclofenac potassium on the success of inferior alveolar nerve block in patients with irreversible pulpitis: a double-blind, randomised controlled clinical trial. Int Endod J. 2011 Apr;44(4):330-6. doi: 10.3797/scipharm.1012-03. Epub 2011 Jan 20.
    3: Yakhno N, Guekht A, Skoromets A, Spirin N, Strachunskaya E, Ternavsky A, Olsen KJ, Moller PL. Analgesic efficacy and safety of lornoxicam quick-release formulation compared with diclofenac potassium: randomised, double-blind trial in acute low back pain. Clin Drug Investig. 2006;26(5):267-77. Review.

    合成参考文献


    参考文献:10.1021/jm901534d
    摘要:Ono K, Ueda H, Yoshizawa Y, Akazawa D, Tanimura R, Shimada I, Takahashi H. Structural basis for platelet antiaggregation by angiotensin II type 1 receptor antagonist losartan (DuP-753) via glycoprotein VI. J Med Chem. 2010 Mar 11;53(5):2087–93. doi: 10.1021/jm901534d.
    参考文献:10.1177/1470320311414453
    摘要:Pouleur AC, Uno H, Prescott MF, Desai A, Appelbaum E, Lukashevich V, Smith BA, Dahlöf B, Solomon SD; ALLAY Investigators. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):483–90. doi: 10.1177/1470320311414453.
    参考文献:10.1177/1470320311415135
    摘要:Shiga Y, Miura S, Mitsutake R, Uehara Y, Inoue A, Saku K. Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):107–12. doi: 10.1177/1470320311415135.
    参考文献:10.1155/2011/687624
    摘要:Voulgari C, Tentolouris N, Stefanadis C. The ECG Vertigo in Diabetes and Cardiac Autonomic Neuropathy. Experimental Diabetes Research. 2011;2011():1–17. doi: 10.1155/2011/687624.
    参考文献:10.1371/journal.pone.0021232
    摘要:Luzardo R, Silva PA, Einicker-Lamas M, Ortiz-Costa S, Tavares do Carmo MDG, Vieira-Filho LD, Paixão ADO, Lara LS, Vieyra A. Metabolic Programming during Lactation Stimulates Renal Na+ Transport in the Adult Offspring Due to an Early Impact on Local Angiotensin II Pathways. PLoS ONE. 2011 Jul 01;6(7):e21232. doi: 10.1371/journal.pone.0021232.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知